INTRODUCTION
 18 
19
Peptic ulcer disease (PUD) and chronic gastritis are most common disorders throughout the 20 world and alleviation of their symptoms is an important goal of treatment [1] . Helicobacter 21
Pylori (H Pylori) is known to play a major role in the development of chronic gastritis, peptic 22 ulcers, and gastric malignancies. Eradication of H. Pylori infection facilitates ulcer healing 23 and prevents recurrence [2, 3] . 24
In the past 30 years, acid suppression therapy has revolutionized the treatment of gastric 25 acid related disorders including GERD and peptic ulcer [4] . The introduction of histamine H 2 26 receptor antagonists and proton pump inhibitors (PPI) has been associated with a marked 27 improvement in the rate of gastric ulcer healing. However, the high relapse rate following 28 treatment cessation with these drugs has led to the examination of the quality of ulcer 29 healing (QOUH) for gastric ulcers, moreover a reduction in gastric mucosal defense factors 30 is now recognized as one of the possible factors responsible for poor QOUH. Potentiation of 31 gastric mucosal defense factors is important for improving the QOUH and reducing the 32 incidence of relapse of gastric ulcers [5] . 33 Lafutidine, a second generation H 2 -receptor antagonist (H 2 -RA) used in clinical practice, has 34 been reported to be more potent than first generation H 2 -RAs. It has been classified as a 35 second generation H 2 -RA because it has long lasting H 2 -receptor blocking activity and unlike 36 famotidine and cimetidine, it suppresses acid secretion both during daytime as well as night 37 time [2, 3] . After oral administration, lafutidine produces a more rapid rise in intragastric pH 38 than rabeprazole 20 mg in fasting and postprandial H. Pylori negative patients, resulting in 39 the early resolution of symptoms [6] . 40
In addition to its antisecretory activity, Lafutidine has gastroprotective actions as it 41 strengthens the mucus barrier of the human gastric mucosa 
MATERIAL AND METHODS

53
This was a comparative, prospective, double-blind, double dummy, active controlled, 54 randomized study conducted at "Global Liver and Gastroenterology Centre", Bhopal, India. 55
The study protocol was approved by an Independent Ethics committee and the study was 56 conducted under the ethical norms laid down by the The visual analog scale (VAS), a scoring system from 0 (lack of symptom) to 100 (high 81 severity) [12] , was used to score the severity of the seven subjective clinical symptoms 82 (Abdominal Pain, Bloating, Belching, Nausea, Vomiting, Loss of Appetite and Heartburn) at 83 baseline and at each follow up visit. The topography and severity of endoscopic gastritis 84 was classified according to the "Sydney System of Endoscopic Classification" [13, 14] . 85
Based on the endoscopy, the topography of gastritis was noted as antrum gastritis, corpus 86 gastritis or both (pangastritis). 87
Peptic ulcer stage was classified using a 6-stage system "Sakita-Miwa classification": The changes in severity of individual symptoms between the visits in each treatment group 107 were compared by "Wilcoxon Rank Sum" Test. A comparative evaluation for the mean score 108 reduction between the two groups was performed by "Mann-Whitney U-test". The 109
proportions of patients were reported as "percentage" along with their "95% confidence 110 interval" (CI) and the comparison between the treatment groups were performed using 111
Fisher's exact test. All data are presented as mean ± standard deviation (S.D) unless stated 112 otherwise. P value less than.05 was considered significant. 113 114 115
RESULTS
117
The study comprised of two groups: patients with gastritis and patients with peptic ulcer. A 118 total of 100 patients, 50 in each group were enrolled. Thus in each treatment group 119 (lafutidine and rabeprazole), there were 50 patients (25 with gastritis and 25 with peptic 120 ulcer). Of the 50 patients who received rabeprazole, five patients, one with peptic ulcer and 121 four with gastritis were lost to follow-up. All patients receiving lafutidine completed the study 122 as per the protocol. 123 There was a significant reduction in the VAS score from the baseline in both the treatment 147 groups (Table 2) . A sustained relief (a score of 0 on the VAS scale) was observed in all the 148 patients, receiving either of the drugs in symptoms of belching and heartburn, at the end of 4 149 weeks. No significant difference in symptom relief for any clinical symptom was observed 150 between the two groups. 151 152 153 
Patient Profile
Resolution of Signs of Endoscopic Peptic Ulcer 176
After 4 weeks of therapy, 72.0% (18/25, 95% CI = 50.61 to 87.93%) and 79.16% (19/24, 177 95% CI = 57.85 to 92.87%) of the patients showed no signs of gastric or duodenal ulcer 178 upon endoscopy in lafutidine and rabeprazole group respectively. No significant difference 179 was observed in the cure rates of ulcer based on ulcer stage among the two groups (Table  180 3). The proportion of patients with complete cure from gastric or duodenal ulcer 181 corresponded with a reduction in the ulcer size as well (Table 4 ) 182 183 In this study, it was also observed that a higher proportion of patients in lafutidine group 233 became H. Pylori negative at the end of 4 weeks therapy in comparison to those in 234 rabeprazole group. 235
Overall both the drugs were well tolerated and no adverse events were reported by patients 236 in both the treatment groups. The current study has its limitation in terms of smaller sample 237 size and subjective interpretation of VAS scale as it represents patient-weighted assessment 238 of symptoms but it was supported with proven diagnosis like endoscopy and histology. 239
Further trials might be required to validate the reliability of lafutidine in gastritis and peptic 240 ulcer 241 
CONCLUSION
